Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lacto-B
- Development stage
- Preclinical
- Lead developer
- Novell Pharmaceutical Laboratories
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lacto-B is a probiotic dietary supplement and microbial therapy primarily used to treat diarrhea and restore the balance of intestinal microflora, particularly in children and malnourished populations. Manufactured as a powder in sachets, it contains a specific blend of beneficial bacteria including *Lactobacillus acidophilus*, *Bifidobacterium longum*, and *Streptococcus thermophilus*. The formulation is often enriched with essential vitamins such as thiamine (B1), riboflavin (B2), pyridoxine (B6), niacin (B3), and ascorbic acid (C), as well as zinc. Lacto-B works by populating the gastrointestinal tract with healthy bacteria that competitively exclude pathogens, enhance the mucosal barrier, and modulate the host's immune response. Research indicates that its administration can lead to a significant decrease in pro-inflammatory cytokines like Tumor Necrosis Factor (TNF) and an increase in anti-inflammatory cytokines such as Interleukin-10 (IL-10).
- Brand names
- Lacto-B
- Other names
- Lacto-B cultureProbiotic culture
02
Targets
IL10 (Interleukin-10)
Beyond the preview
Go deeper on Lacto-B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lacto-B.